Lineage Provides Update on ReSonance® Program for Hearing Loss
Stocks in this Quantisnow insightHealth Care
Historical context for LCTX
Across the 17 sessions after earlier LCTX headlines, the stock closed higher 12 times and lower 5 times, with a median move of 2.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | LCTX | SPY |
|---|---|---|---|
| Sep 8, 2026 | Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform | +0.9% | -0.5% |
| Aug 7, 2026 | Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | -2.7% | +0.6% |
| Jul 30, 2026 | Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 | +4.7% | +1.7% |
| Jul 13, 2026 | Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease | -5.5% | -0.8% |
| Jul 6, 2026 | Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit | -1.5% | +0.9% |
| May 13, 2026 | Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | -3.8% | +0.6% |
Keep researching LCTX
- LCTX insider tradesEvery buy and sale reported by Lineage Cell Therapeutics Inc. officers, directors and large holders.
- LCTX earnings historyPast Lineage Cell Therapeutics Inc. earnings releases, newest first.
- LCTX financial statementsRevenue, profit, cash flow and balance sheet from Lineage Cell Therapeutics Inc.'s SEC filings.
Quantisnow market dataAMEX
LCTX
Lineage Cell Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
Get push alerts for LCTX
Full LCTX profile on Quantisnow Follow LCTX and get a push notification the moment its next story breaks.